Abstract:Yashi Ruan, 1, &ast Lixia Guan, 2, &ast Yuting Wang, 2 Yifei Geng, 2 Xiaoran Wang, 2 Miao-Miao Niu, 2 Li Yang, 1 Cen Xu, 1 Zhen Xu 1 1 Department of Urology, Reproductive Medicine and Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, People's Republic of China; 2 Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Yang; Cen Xu, Department of Urology, Reproductive Medicine and Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, People's Republic of China, Email ; Purpose: Dual inhibition of ataxia telangiectasia mutated (ATM) and histone deacetylase 2 (HDAC2) may be a potential strategy to improve antitumor efficacy in testicular cancer. Methods: A combined virtual screening protocol including pharmacophore modeling and molecular docking was used for screening potent dual-target ATM/HDAC2 inhibitors. In order to obtain the optimal lead compound, the dual ATM/HDAC2 inhibitory activity of the screened compounds was further evaluated using enzyme inhibition methods. The binding stability of the optimal compound to the dual targets was verified by molecular dynamics (MD) simulation. MTT assay and in vivo antitumor experiment were performed to validate antitumor efficacy of the optimal compound in testicular cancer. Results: Here, we successfully discovered six potent dual-target ATM/HDAC2 inhibitors (AMHs 1– 6), which exhibited good inhibitory activity against both ATM and HDAC2. Among them, AMH-4 showed strong inhibitory activity against both ATM (IC 50 = 1.12 ± 0.03 nM) and HDAC2 (IC 50 = 3.04 ± 0.08 nM). MD simulation indicated that AMH-4 binds to ATM and HDAC2 with satisfactory stability. Importantly, AMH-4 had significant antiproliferative activity on human testicular tumor cells, especially NTERA-2 cL.D1 cells, and no inhibitory effect on normal human testicular cells. In vivo experiments exhibited that AMH-4 was more effective than lartesertib and vorinostat in inhibiting the growth of NTERA-2 cL.D1 xenograft tumors with low toxicity. Conclusion: Overall, these results suggest that AMH-4 is an effective and low toxicity candidate for the treatment of testicular germ cell tumors. Keywords: ataxia telangiectasia mutated, histone deacetylase 2, dual-targeting inhibitors, testicular germ cell tumors, structure-based virtual screening Testicular germ cell tumors (TGCT) are the most common type of testicular malignancy, emerging most frequently in males between the ages of 15 and 40. 1,2 During the past 20 years, the incidence of testicular cancer has continued to rise in many countries and is expected to increase further in the future. 3,4 Currently, surgery and standard-dose chemotherapy are the main methods of treating TGCT. 5 Approximately 80–90% of metastatic TGCT have a high cure rate after standard dose cisplatin chemotherapy. 5 However, testicular cancer survivors treated with cisplatin face many toxic side effects, including ototoxicity, neuropathy, cardiovascular toxicity, infertility, and secondary malignancies. 6 In addition, young patients may face a range of long-term psychosocial issues after treatment, including mental health, gender relations and work issues, which can significantly affect their overall quality of life. 7 For TGCT-resistant patients who have failed multiple chemotherapy regimens, the clinical cure rate is extremely low. 6 Therefore, the development of novel drugs for testicular cancer is indeed urgent. At present, dual-target therapy is a promising treatment strategy with fewer side effects, lower toxicity, and the potential to overcome drug resistance in cancer treatment. 8–10 ATM plays a central role in protecting the genome from DNA damage through intact DNA repair pathways. 11–13 There are growing evidences suggest that ATM can coordinate homologous recombination (HR) and non-homologous end joining (NHEJ) pathways to repair DNA double-strand breaks (DSBs) and maintain genomic integrity. 11,14,15 In response to DSBs, ATM kinase undergoes self-phosphorylation and subsequently phosphorylates several downstream substrates, including p53, p21, Nbs1, and KAP1, ultimately mediating DNA repair and cell cycle regulation. 12,16,17 Studies have shown that abnormal ATM, characterized by serine 1981 phosphorylation, can be observed in testicular germ cell tumors. 18 Therefore, the inhibiti -Abstract Truncated-

Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening

Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study

Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Discovery of novel 7,7-dimethyl-6,7-dihydro-5 H -pyrrolo[3,4- d ]pyrimidines as ATR inhibitors based on structure-based drug design

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors

Discovery of 4-{4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1h-indole (AZ20): a Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity.

A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth

Synthesis of dihydrofuran-3-one and 9,10-phenanthrenequinone hybrid molecules and biological evaluation against colon cancer cells as selective Akt kinase inhibitors

Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies

Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo

Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Discovery and Optimization of 4-Anilinoquinazoline Derivatives Spanning ATP Binding Site and Allosteric Site As Effective EGFR-C797S Inhibitors

Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Virtual Screening-Based Study of Novel Anti-Cancer Drugs Targeting G-Quadruplex